Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
ABSTRACTHerpes zoster (HZ) is a debilitating vaccine-preventable disease. Impairment of cell-mediated immunity, as observed with aging and immunosuppressive disorders and therapies, increases risk. Recombinant zoster vaccine (RZV) is efficacious against HZ in adults aged ≥50 years in different setti...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2278362 |
| _version_ | 1797354190085816320 |
|---|---|
| author | Agnes Mwakingwe-Omari Nicolas Lecrenier Abdi Naficy Desmond Curran Inga Posiuniene |
| author_facet | Agnes Mwakingwe-Omari Nicolas Lecrenier Abdi Naficy Desmond Curran Inga Posiuniene |
| author_sort | Agnes Mwakingwe-Omari |
| collection | DOAJ |
| description | ABSTRACTHerpes zoster (HZ) is a debilitating vaccine-preventable disease. Impairment of cell-mediated immunity, as observed with aging and immunosuppressive disorders and therapies, increases risk. Recombinant zoster vaccine (RZV) is efficacious against HZ in adults aged ≥50 years in different settings, and in immunocompromised adults aged ≥18 years who are at increased risk of developing HZ. RZV is the first and only HZ vaccine approved for use in immunocompromised adults globally, including in Europe and the US. RZV has a clinically acceptable safety profile and elicits robust immune responses in adults aged ≥50 years, and in immunocompromised adults aged ≥18 years who are at increased risk of HZ. Additionally, RZV is efficacious against HZ complications such as post-herpetic neuralgia and HZ-related pain. This review updates knowledge from a randomized controlled trial setting on the efficacy, safety, immunogenicity, and impact on quality of life of RZV. |
| first_indexed | 2024-03-08T13:46:52Z |
| format | Article |
| id | doaj.art-ebde464ac4a046c49a85456a4ca84239 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-08T13:46:52Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-ebde464ac4a046c49a85456a4ca842392024-01-16T09:08:39ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-12-0119310.1080/21645515.2023.2278362Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studiesAgnes Mwakingwe-Omari0Nicolas Lecrenier1Abdi Naficy2Desmond Curran3Inga Posiuniene4Clinical Sciences, GSK, Rockville, MD, USAMedical Affairs Department, GSK, Wavre, BelgiumClinical Sciences, GSK, Rockville, MD, USAEvidence and Outcome Department, GSK, Wavre, BelgiumMedical Affairs Department, GSK, Wavre, BelgiumABSTRACTHerpes zoster (HZ) is a debilitating vaccine-preventable disease. Impairment of cell-mediated immunity, as observed with aging and immunosuppressive disorders and therapies, increases risk. Recombinant zoster vaccine (RZV) is efficacious against HZ in adults aged ≥50 years in different settings, and in immunocompromised adults aged ≥18 years who are at increased risk of developing HZ. RZV is the first and only HZ vaccine approved for use in immunocompromised adults globally, including in Europe and the US. RZV has a clinically acceptable safety profile and elicits robust immune responses in adults aged ≥50 years, and in immunocompromised adults aged ≥18 years who are at increased risk of HZ. Additionally, RZV is efficacious against HZ complications such as post-herpetic neuralgia and HZ-related pain. This review updates knowledge from a randomized controlled trial setting on the efficacy, safety, immunogenicity, and impact on quality of life of RZV.https://www.tandfonline.com/doi/10.1080/21645515.2023.2278362Herpes zosterimmunocompromisedpost-herpetic neuralgiapreventionRZVshingles |
| spellingShingle | Agnes Mwakingwe-Omari Nicolas Lecrenier Abdi Naficy Desmond Curran Inga Posiuniene Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies Human Vaccines & Immunotherapeutics Herpes zoster immunocompromised post-herpetic neuralgia prevention RZV shingles |
| title | Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies |
| title_full | Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies |
| title_fullStr | Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies |
| title_full_unstemmed | Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies |
| title_short | Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies |
| title_sort | recombinant zoster vaccine in immunocompetent and immunocompromised adults a review of clinical studies |
| topic | Herpes zoster immunocompromised post-herpetic neuralgia prevention RZV shingles |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2023.2278362 |
| work_keys_str_mv | AT agnesmwakingweomari recombinantzostervaccineinimmunocompetentandimmunocompromisedadultsareviewofclinicalstudies AT nicolaslecrenier recombinantzostervaccineinimmunocompetentandimmunocompromisedadultsareviewofclinicalstudies AT abdinaficy recombinantzostervaccineinimmunocompetentandimmunocompromisedadultsareviewofclinicalstudies AT desmondcurran recombinantzostervaccineinimmunocompetentandimmunocompromisedadultsareviewofclinicalstudies AT ingaposiuniene recombinantzostervaccineinimmunocompetentandimmunocompromisedadultsareviewofclinicalstudies |